Rabies Vaccine Recommended for EU Approval
The European Medicines Agency has backed a new rabies vaccine for both pre-exposure and post-exposure use in all ages.
Updated on Sept. 22, 2026 in Allergies
Live Poll
Should regulatory panels approve new vaccines for use across all age groups?
The European Medicines Agency Committee for Medicinal Products for Human Use has issued a positive opinion for VaxRabeo, a purified inactivated rabies vaccine. This development marks a key step in providing broad protection for all age groups against a virus that is nearly 100% fatal once clinical symptoms emerge.
Why it matters
Because dog bites are responsible for 99% of human rabies cases, having a reliably effective vaccine for both preventative and emergency use is critical. The recommendation ensures that, pending final approval, clinicians will have a new tool for managing high-risk exposures across all age populations.
Regulatory review confirmed that the vaccine induces neutralizing antibodies against the surface glycoprotein of the rabies virus in both children and adults. Clinical trials noted injection-site pain and myalgia, as well as irritability in children aged 12 to 23 months.
The players
European Medicines Agency
An agency of the European Union responsible for the scientific evaluation, supervision, and safety monitoring of medicines.
European Commission
The executive branch of the European Union that makes final decisions on drug marketing authorizations.
The details
VaxRabeo is administered as an injectable suspension prepared from a powder and solvent. Once in the body, the vaccine triggers the production of neutralizing antibodies that target the surface glycoprotein of the rabies virus, effectively priming the immune system to recognize and neutralize the pathogen before it can enter the central nervous system. This standardized response provides necessary defense for individuals exposed to animals, particularly dogs, which account for the vast majority of human rabies infections.
Timeline
The Committee for Medicinal Products for Human Use adopted its positive opinion in September 2026.
A final marketing authorization decision from the European Commission is expected in approximately 67 days.
Health Landscape
This recommendation follows the standard CHMP procedure for evaluating inactivated viral vaccines prior to centralized EU-wide distribution. It represents a significant update to the current standard of care by expanding the available options for both pre-exposure and post-exposure prophylaxis.
If you are traveling to regions where rabies is endemic or handling animals, discuss your risk and vaccination status with your physician. This development does not change current care protocols until final authorization is granted and the vaccine becomes available in local health systems.
The takeaway
Rabies remains a lethal disease that requires immediate medical intervention after any potential exposure. Always confirm your vaccination status and seek immediate professional care if you have been bitten or scratched by an animal, as immediate treatment is the only way to prevent symptom onset.
Further reading
For more information on preventing reactions and understanding vaccine safety, visit the Allergies section.
Source note: This article includes information reported by Medscape.
Live Poll
Should regulatory panels approve new vaccines for use across all age groups?
